Drug Trial Radar · NCT07842640
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Aug 27, 2026
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Ascletis Pharma (China) Co., LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection
Conditions
- Chronic Weight Management
Interventions
ASC35 Injection B, for subcutaneous useDrug
ASC35 Injection B is an investigational once-monthly formulation of ASC35 administered by subcutaneous injection.
ASC35 Placebo Injection B, for subcutaneous useDrug
ASC35 Placebo Injection B is a placebo injection matching ASC35 Injection B
TirzepatideDrug
Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: Baseline and Day 141
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ascletis Clinical Site
Baltimore, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.